Jiangsu Hengrui Pharmaceuticals announced that the company's application for the marketing authorization of SHR4640 tablets has been accepted by the National Medical Products Administration. SHR4640 tablets are a self-innovated Class 1 pharmaceutical for the long-term treatment of primary gout with hyperuricemia.
恒瑞医药：SHR4640片药品上市许可申请获受理
Jiangsu Hengrui Pharmaceuticals: The application for the marketing authorization of SHR4640 tablets has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated